Fog Pharmaceuticals, founded with the mission to make all disease targets druggable, is a clinical-stage biopharmaceutical company focused on developing cell-penetrating mini-proteins for cancer treatment. Their core product, Helicons™, represents a new class of precision medicines designed to overcome the limitations of current therapies. By integrating advanced technologies, Fog Pharmaceuticals aims to accelerate drug discovery and target previously intractable diseases, with a primary focus on oncology.

Notable figures affiliated with Fog Pharmaceuticals include seasoned biotech entrepreneurs and leading scientists in the field of drug discovery. The company has attracted significant investment from prominent venture capital firms, enabling rapid advancement in their research and development efforts. Key achievements include the development of their proprietary discovery engine and the successful progression of Helicons™ into clinical trials. Fog Pharmaceuticals' innovative approach has the potential to significantly impact cancer treatment and broaden the scope of precision medicine.